@article{WesterKellerSchotteliusetal.2015, author = {Wester, Hans J{\"u}rgen and Keller, Ulrich and Schottelius, Margret and Beer, Ambros and Philipp-Abbrederis, Kathrin and Hoffmann, Frauke and Šimeček, Jakub and Gerngross, Carlos and Lassmann, Michael and Herrmann, Ken and Pellegata, Natalia and Rudelius, Martina and Kessler, Horst and Schwaiger, Markus}, title = {Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging}, series = {Theranostics}, volume = {5}, journal = {Theranostics}, number = {6}, doi = {10.7150/thno.11251}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-144537}, pages = {618-630}, year = {2015}, abstract = {Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.}, language = {en} }